News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GPC Biotech AG (GPCG.DE) Schedules Conference Call on August 18th to Discuss First Half 2009 Financial Results



8/11/2009 10:45:32 AM

MARTINSRIED, GERMANY and MUNICH, GERMANY and PRINCETON, NJ--(Marketwire - August 11, 2009) -

GPC Biotech AG (FRANKFURT: GPC) (XETRA: GPC) today announced that it will hold a conference call on Tuesday, August 18, 2009 to discuss its financial results for the second quarter and first half of 2009. The results will be published on August 18th in advance of the call.

Participants may listen via live webcast, accessible through the GPC Biotech Web site at www.gpc-biotech.com, or via telephone. A replay will be available via the Web site following the live event. The call, which will be conducted in English, will be held on August 18 at 15:00 CET/9:00 AM ET.

The dial-in numbers for the call are as follows:

Participants in Europe:      0049 (0) 69 667775756
                             0044 (0)20 3003 2666
Participants in the U.S.:    1-646-843-4608

About GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on developing anti-cancer drugs. The Company currently has two programs in clinical development: satraplatin, an oral platinum compound, and RGB-286638, a multi-targeted protein kinase inhibitor. The Company's shareholders have approved a merger agreement pursuant to which the Company will combine its business with Agennix, Incorporated, a privately held biotechnology company located in Houston, Texas. Agennix is developing oral talactoferrin, a product candidate that is currently in Phase 3 trials for non-small cell lung cancer. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at www.gpc-biotech.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.


For further information, please contact:

GPC Biotech AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com

In the U.S.:
Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609-524-5884
usinvestors@gpc-biotech.com

Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0

Raimund Gabriel
raimund.gabriel@mc-services.eu

Hilda Juhasz
hilda.juhasz@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren (Rigg) Williams
Vice President
Phone: +44 207 936 9325
lrigg@troutgroup.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES